Oxford Immunotec

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test and the T-SPOT.PRT test are the Company's second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.
Company Growth (employees)
Type
Public
HQ
Milton, GB
Founded
2001
Size (employees)
432 (est)
Oxford Immunotec was founded in 2001 and is headquartered in Milton, GB

Key People at Oxford Immunotec

Peter Wrighton-Smith

Peter Wrighton-Smith

CEO
Richard M. Altieri

Richard M. Altieri

CFO

Oxford Immunotec Office Locations

Oxford Immunotec has offices in Milton, Kohoku Ward, Marlborough, Shanghai
Milton, GB (HQ)
115D Innovation Drive Milton Park Abingdon Oxfordshire
Shanghai, CN
1701, Tower 2, Shanghai Arch Hongqiao, 533 Loushanguang Road
Marlborough, US
200 700 Nickerson Rd
Kohoku Ward, JP
8F Nisso Bldg. No16, 3-8-8 Shinyokohama

Oxford Immunotec Metrics

Oxford Immunotec Financial Metrics

Revenue (2015)

£46.4 m

Revenue growth (2014-15), %

27%

Gross profit

£24.6 m

Gross profit margin (2015), %

53%

Market capitalization (21-Mar-2017)

$349 m

Closing share price (21-Mar-2017)

$15.7
Oxford Immunotec's current market capitalization is $349 m.
Oxford Immunotec's revenue was reported to be £46.4 m in FY, 2015 which is a 26.8% increase from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

£25.5 m£36.6 m£46.4 m

Revenue growth, %

44%27%

Cost of goods sold

£12.2 m£17.8 m£21.8 m

Gross profit

£13.3 m£18.9 m£24.6 m

Gross profit Margin, %

52%52%53%

Operating expense total

£17.7 m£34.9 m£42.4 m

Oxford Immunotec Market Value History

Oxford Immunotec Online Presence

Oxford Immunotec Company Life

You may also be interested in